Safety Outcomes:
We combined the data retrieved from the five trials for serious adverse
events (SAEs) and adverse events (AEs) such as deaths, myocardial
infarctions, recurrent strokes, hernia, hemorrhage of the digestive
tract, fever (>38 °C), hemorrhagic transformation at 24
hours, lung infection, urinary tract infection, herpes virus infection,
abnormal laboratory liver-function test, gastrointestinal disorders,
arrhythmia, and macular edema. The collected data of common AEs are
displayed in Table 2. Data analysis was performed using statistical
software provided by Stata16.0.We did not find any significant
difference between the fingolimod and standardized treatment groups in
terms of SAEs and AEs.
Table 2. Safety outcomes in the meta-analysis